Home › Compound Library › Ibogaine

Ibogaine

Psychedelicoral · inferred

Indole alkaloid from Tabernanthe iboga root bark with a unique pharmacological profile among psychedelics. Anti-addictive properties — interrupts opioid withdrawal and reduces craving through complex polypharmacology (NMDA antagonism, kappa-opioid agonism, sigma-2 agonism, 5-HT2A agonism, SERT inhibition). Produces prolonged experience (24-72h including visionary phase). CYP2D6 substrate metabolized to noribogaine (active metabolite persisting >24h). QTc prolongation risk — cardiotoxicity at high doses limits therapeutic window. Fatalities reported primarily at very high doses or with comorbidities.

Projected serum levels — 500 mg, as needed (shown daily)

Ibogaine
Ibogaine modeled serum levels, 500 mg as needed (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 62.5 125 188 250 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 500 mg as needed (shown daily) (oral).

Modeled steady state after ~1 days: peak ≈ 246 mg, trough ≈ 30.0 mg body load. Population-based estimate over 15 days for a 500 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Psychedelic
Route modeled
Oral
Model confidence
inferred
Half-life
6 h
Common dose
500 mg
Suggested maximum
1.5k mg/day
Reference dose range
300–1.5k mg (single dose)
Suggested cadence
as needed (shown daily)

Documented interactions

  • contraindicated
    MDA (3,4-Methylenedioxyamphetamine) + Ibogaine CYP inhibition

    MDA (3,4-Methylenedioxyamphetamine) mechanism_based of CYP2D6 predicted to change Ibogaine AUC by ~10.00x

  • contraindicated
    MDMA (Ecstasy) + Ibogaine CYP inhibition

    MDMA (Ecstasy) mechanism_based of CYP2D6 predicted to change Ibogaine AUC by ~10.00x

  • contraindicated
    Paroxetine (Paxil) + Ibogaine CYP inhibition

    Paroxetine (Paxil) mechanism_based of CYP2D6 predicted to change Ibogaine AUC by ~10.00x

  • danger
    1P-LSD (1-Propionyl-LSD) + Ibogaine Serotonin risk

    1P-LSD (1-Propionyl-LSD) and Ibogaine both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + Ibogaine Serotonin risk

    25I-NBOMe and Ibogaine both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Ibogaine Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Ibogaine both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 158 modeled interaction pairings for ibogaine across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Ibogaine in the treatment of heroin withdrawal Mash DC et al. · Annals of the New York Academy of Sciences, 1998 DOI

    Foundational clinical report from the MAPS-sponsored ibogaine program demonstrating that ibogaine effectively interrupts opioid withdrawal symptoms and reduces craving, with noribogaine identified as the long-acting…

  2. Ibogaine treatment outcomes for opioid dependence from a 12-month follow-up observational study (New Zealand) Noller GE et al. · The American Journal of Drug and Alcohol Abuse, 2018 DOI

    Observational study of 14 patients undergoing ibogaine detox at a New Zealand clinic; 50% remained opioid-free at 12 months. One death occurred during treatment, highlighting the need for medical monitoring and the…

2 published studies referenced in the app, each with a plain-language summary.